News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Immunotherapy agents set to transform melanoma treatment

Immunotherapy agents set to transform melanoma treatment

Speaking at the national Melanoma Summit in Auckland, a Los Angeles-based melanoma expert has told delegates that a new class of anti-cancer agents, known as immunotherapies, is transforming the treatment of patients with metastatic melanoma – melanoma that has spread throughout the body.

Antoni Ribas, Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles, has been the lead investigator on several large clinical trials of cutting-edge cancer treatments, including targeted therapies and immunotherapies.

Targeted therapies include BRAF and MEK inhibitors, such as vemurafenib, cobemetinib, dabrafenib and trametinib, which more precisely identify and kill cancer cells. Immunotherapies use the body’s own immune system to attack the tumour.

One group of immunotherapy agents, including the drugs pembrolizumab and nivolumab, bind to and block a molecule called PD-1 to “take the brakes off” the immune system and allow the body to detect and destroy cancer cells.

Professor Ribas says that although targeted therapies were an important advance in cancer treatment and the majority of patients obtain benefit from these agents, at least initially, there is growing evidence that immunotherapy drugs are better than other treatment strategies for a subset of patients with metastatic melanoma.

“Some patients are going for years without a relapse. We’re very conservative about how we call things, but it’s possible that some are cured.”

There is also the potential to use immunotherapies in combination with targeted agents and chemotherapy to achieve an even better response.

Professor Ribas says the advances in melanoma treatment didn’t happen by chance.

“We’re taking science from the lab to the patient and starting a series of combination studies to be able to overcome the barriers for patients who don’t respond.

“In addition to melanoma, immunotherapy has potential in a wide range of other cancers; clinical trials have studied immunotherapy agents in 30 different types of cancer, with evidence of activity in 15 of these.”


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines


Howard Davis Review: Reclaiming The N-Word - Spike Lee's BlacKkKlansman

Black resistance to institutional racism in the US has a long, tangled, and traumatic intellectual history. Although we may have assumed much too easily that white supremacists like David Duke had become marginalised as a political force, in reality they never really disappeared ... More>>

Howard Davis Review: The Minstrel in The Gallery - Sam Hunt's Selected Poems

Perhaps the most striking aspect of Sam Hunt's poetry is its quality of urgent authenticity. Encountering this latest compilation, the reader is immediately struck by its easy accessibility, tonal sincerity, and lack of linguistic pretension ... More>>

A Matter Of Fact: Truth In A Post-Truth World

How do we convincingly explain the difference between good information and misinformation? And conversely, how do we challenge our own pre-conceived notions of what we believe to be true? More>>


Scoop Review Of Books: The Road To Unfreedom

Valerie Morse: Yale professor of history Tim Snyder publishes a stunning account of the mechanisms of contemporary Russian power in US and European politics. In telling this story he presents both startling alarms for our own society and some mechanisms of resistance. More>>


Doing Our Bit: An Insider's Account Of New Zealand Political Campaigning

In 2013, Murdoch Stephens began a campaign to double New Zealand’s refugee quota. Over the next five years he built the campaign into a mainstream national movement – one that contributed to the first growth in New Zealand’s refugee quota in thirty years. More>>



  • Wellington
  • Christchurch
  • Auckland